Syringes Market: as GLP-1 obesity therapeutics push biologics fill-finish demand to a scale the industry has never manufactured against before, the largest prefillable syringe makers are racing to solve the specific high-injection-force problem that limits patient self-injection acceptance at high-concentration dose volumes, so the physical syringe barrel itself has become as consequential a bottleneck to obesity drug access as the underlying pharmaceutical manufacturing capacity.

The global syringes market size was USD 18.74 Billion in 2025 and is expected to register a revenue CAGR of 7.7% during the forecast period. Market revenue growth is driven by factors such as GLP-1 and biologics drug delivery volume growth expanding prefillable syringe demand across pharmaceutical fill-finish operations, safety syringe adoption continuing to displace conventional hypodermic syringes across hospital medication administration, and domestic manufacturing capacity expansion addressing supply chain resilience concerns following FDA import quality warnings. The first driving factor is GLP-1 and biologics drug delivery volume growth, which directly expands prefillable syringe demand as pharmaceutical manufacturers scale fill-finish capacity for obesity and chronic disease therapeutics. Prefillable and prefilled syringes account for a substantial share of total 2025 market revenue, reflecting this category's centrality to the fastest-growing pharmaceutical delivery format. The second driving factor is safety syringe adoption, which continues displacing conventional hypodermic syringes across hospital medication administration under sustained needlestick injury prevention regulatory requirements. The third driving factor is domestic manufacturing capacity expansion, as the largest syringe manufacturers invest in US and European production capacity to address supply chain resilience concerns following FDA quality warnings on imported plastic syringes. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single prefillable syringe platform engineered specifically to solve high-concentration biologic injection force converts a pharmaceutical company's formulation challenge into a syringe manufacturer's addressable design win, which lets the syringe manufacturer capture fill-finish contract volume tied directly to the pace of GLP-1 and biologics commercial scale-up rather than competing on conventional syringe merits alone. Because a high-concentration biologic formulation like a GLP-1 therapeutic in the 1mL-plus dose volume range creates genuine injection force and patient comfort challenges that limit self-injection acceptance, a syringe platform specifically engineered with a thinner-wall design to reduce this injection force directly addresses the formulation problem holding back broader self-injection adoption, converting a design solution into a pharmaceutical company's formulation-critical fill-finish decision. As a result, demand and revenue share in the prefillable syringe segment are concentrating around manufacturers who can demonstrate a validated solution to the high-concentration injection force problem specifically, and the forecast reflects this formulation-driven design differentiation as a distinct driver of the market's fastest-growing category. For instance, in January 2025, BD unveiled its Neopak XtraFlow Glass Prefillable Syringe at Pharmapack 2025, a thinner-wall design specifically engineered for GLP-1 and biologic injection to reduce the high injection force that limits patient acceptance of self-injection at higher concentration and dose volumes. These are some of the key factors driving revenue growth of the market.

Because FDA safety communications regarding quality issues with certain imported plastic syringes have triggered hospital directives to replace suspect devices, healthcare systems face genuine supply chain transition costs and vendor requalification burden even where a replacement domestic or alternative-source syringe is readily available.

Premium cost for glass prefillable and safety-engineered syringe formats limiting adoption relative to conventional plastic disposable alternatives is a second constraint, since glass prefillable syringes and safety-engineered designs carry meaningfully higher unit cost than standard plastic hypodermic syringes, which creates a genuine cost consideration for high-volume, lower-acuity applications where the premium format's benefits are less clinically critical.

Regulatory harmonisation compliance costs are a third constraint, since the 2026 harmonisation of US quality-system regulations with ISO 13485 obliges every market entrant to upgrade documentation, risk management, and post-market surveillance protocols, elevating barriers to entry and incentivising healthcare providers to narrow vendor rosters toward certified suppliers.

These factors substantially limit syringes market growth over the forecast period.

The clearest driver of demand is GLP-1 and biologics drug delivery volume growth, which directly expands prefillable syringe demand as pharmaceutical manufacturers scale fill-finish capacity for obesity and chronic disease therapeutics to a production scale the industry has not previously manufactured against. A pharmaceutical company scaling GLP-1 fill-finish capacity to hundreds of millions of units annually to meet obesity treatment demand requires a corresponding scale-up in prefillable glass syringe barrel procurement, so the downstream effect on syringe manufacturers tracks pharmaceutical fill-finish capacity investment directly. Prefillable and prefilled syringes account for a substantial share of total 2025 market revenue, and in April 2025, Gerresheimer partnered with Injecto to launch silicone-oil-free and PFAS-free syringe systems specifically addressing biologics formulation compatibility requirements increasingly demanded by pharmaceutical fill-finish customers. The effect on the market is that prefillable syringe manufacturer capacity investment and design innovation increasingly tracks the pace of GLP-1 and biologics commercial scale-up rather than conventional hospital syringe replacement cycles. These are some of the key factors driving revenue growth of the market.

The second driver is safety syringe adoption, which continues displacing conventional hypodermic syringes across hospital medication administration under sustained needlestick injury prevention regulatory requirements that have shaped this market for over two decades. A conventional hypodermic syringe carries genuine needlestick injury risk for healthcare workers during and after use, so safety-engineered auto-disable and retractable designs that eliminate this risk continue capturing share in jurisdictions with active regulatory enforcement of needlestick prevention standards. In April 2025, argenx received FDA clearance for a patient-self-injected prefilled syringe format of Vyvgart Hytrulo, simplifying treatment for generalised myasthenia gravis and reflecting the continued shift of complex biologic therapies toward self-administered prefilled and safety-engineered syringe formats. The effect on the market is that safety and self-injection-appropriate syringe formats continue capturing share from conventional designs across both institutional and home-administered therapeutic categories. These are some of the key factors driving revenue growth of the market.

BD's January 2025 Neopak XtraFlow launch specifically targets the high injection force problem limiting patient acceptance of GLP-1 self-injection at 1mL-plus dose volumes. As pharmaceutical companies scale GLP-1 fill-finish capacity to hundreds of millions of units annually, syringe barrel design has become a genuine bottleneck to obesity drug accessibility.

The third driver is domestic manufacturing capacity expansion, as the largest syringe manufacturers invest in US and European production capacity to address supply chain resilience concerns following FDA quality warnings on imported plastic syringes. FDA safety communications regarding quality issues with certain imported plastic syringes have triggered hospital directives to replace suspect devices, so manufacturers investing in verified domestic or alternative-source production capacity directly address a genuine institutional buyer concern about supply chain reliability and product quality assurance. In February 2025, Terumo and Vygon SA announced a strategic partnership to co-develop next-generation syringe and needle systems specifically for perioperative and vaccination use, reinforcing manufacturing and design collaboration between established European and Japanese syringe manufacturers. The effect on the market is that manufacturing capacity and supply chain transparency are becoming genuine competitive differentiators for hospital system procurement decisions, not solely product design considerations. These are some of the key factors driving revenue growth of the market.

However, the syringes market faces severe adoption constraints from FDA quality and supply chain scrutiny on imported plastic syringes requiring hospital systems to transition suppliers, and premium cost for glass prefillable and safety-engineered syringe formats limiting adoption relative to conventional plastic disposable alternatives.

Because FDA safety communications regarding quality issues with certain imported plastic syringes have triggered hospital directives to replace suspect devices, healthcare systems face genuine supply chain transition costs and vendor requalification burden even where a replacement domestic or alternative-source syringe, such as those from Terumo's expanded Vygon SA partnership, is readily available.

Premium cost for glass prefillable and safety-engineered syringe formats limiting adoption relative to conventional plastic disposable alternatives compounds this, since these formats carry meaningfully higher unit cost than standard plastic hypodermic syringes, which creates a genuine cost consideration for high-volume, lower-acuity applications where the premium format's benefits are less clinically critical.

Regulatory harmonisation compliance costs are the third constraint, since the 2026 harmonisation of US quality-system regulations with ISO 13485, effective February 2026, obliges every market entrant to upgrade documentation, risk management, and post-market surveillance protocols, elevating barriers to entry and incentivising healthcare providers to narrow vendor rosters toward certified suppliers.

These factors substantially limit syringes market growth over the forecast period.

Based on product type, the global syringes market is segmented into hypodermic, safety, prefillable or prefilled, insulin, and specialty syringes. Prefillable and prefilled syringes hold the largest revenue share, because GLP-1 and biologics fill-finish demand commands substantially higher per-unit pricing than conventional hypodermic formats, which suits a market where the fastest-growing pharmaceutical delivery format commands the largest revenue category. Safety syringes remain an essential category for hospital medication administration under sustained regulatory requirements. Insulin syringes are expected to register a significant revenue growth rate in the global syringes market over the forecast period, driven by rising global diabetes prevalence sustaining baseline demand alongside pen and pump delivery alternatives.

Based on material, the global syringes market is segmented into plastic, glass, and stainless steel materials. Glass holds a significant revenue share, because borosilicate glass remains the preferred material for prefillable syringes containing sensitive biologic and GLP-1 formulations requiring superior barrier properties, which ties directly back to the formulation-driven demand described in the market's primary demand driver. Glass is also expected to register the fastest revenue growth rate in the global syringes market over the forecast period, driven by BD's Neopak XtraFlow and Gerresheimer's expanded prefillable glass syringe capacity.

Based on usage, the global syringes market is segmented into single-use disposable and reusable or multi-use syringes. Single-use disposable syringes hold the overwhelming majority of market revenue, because eliminating cross-contamination risk entirely remains the dominant procurement standard across the majority of clinical and pharmaceutical fill-finish applications. Reusable or multi-use syringes are expected to register a moderate revenue growth rate in the global syringes market over the forecast period, reflecting continued niche use in select laboratory and veterinary applications.

Based on regional analysis, the syringes market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of GLP-1 and biologics fill-finish investment and pharmaceutical manufacturing activity creates the deepest and most technologically advanced syringe demand globally, and because BD, Gerresheimer, and Schott Pharma all maintain significant commercial presence in the US market. BD's January 2025 Neopak XtraFlow launch and continued domestic manufacturing investment specifically reinforce the depth of US-anchored prefillable syringe innovation. The concentration of FDA regulatory activity in the country also means new syringe safety and quality standards are typically established in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and Switzerland represent significant national markets within Europe, anchored by Gerresheimer's German headquarters and B. Braun's established European manufacturing base. Terumo's expanded partnership with France-based Vygon SA specifically reinforces the region's role in syringe and needle system co-development. The result is steady rather than rapid growth, shaped more by EU MDR compliance requirements than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and India represent two of the largest national markets within the region, anchored by Terumo's and Nipro's Japanese headquarters and Hindustan Syringes' Indian manufacturing base supporting Gavi programme auto-disable syringe exports. The region's dual role as both a major manufacturing hub and a rapidly expanding vaccination and healthcare access market leaves considerably more room for growth than in the already syringe-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding pharmaceutical fill-finish and hospital procurement activity driving early syringe demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised borosilicate glass and cyclic olefin polymer resins that Latin American syringe manufacturers depend on, an effect expected to run through 2026 and slow syringes adoption beyond Brazil's and Mexico's main manufacturing centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding pharmaceutical manufacturing investment and the UAE's regional distribution hubs represent the primary investment centres for syringes adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the fill-finish and hospital procurement infrastructure needed to support advanced syringe platforms at scale.